bluebird bio (NASDAQ: BLUE) reported Q4 EPS of ($1.29), $0.18 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $1.47 million versus the consensus estimate of $3.21 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.